Product
Androgen deprivation therapy (ADT)
1 clinical trial
1 indication
Indication
Prostate CancerClinical trial
A Single-arm, Open-label Phase 2 Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy (ADT) in Chinese Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)Status: Recruiting, Estimated PCD: 2024-10-26